

Inbiomotion brings MAF Test® for breast cancer prognosis in South Korea

May 26, 2026 | News

To increase the survival of 8 out of 10 of the approximately 34,000 breast cancer patients diagnosed each year



HJ HyupJin, a South Korean healthcare and precision diagnostics company, and Inbiomotion, proprietors of MAF Test® for identifying high-risk early-stage breast cancer patients, have signed an agreement to start offering the MAF Test® in South Korea.

This agreement represents a new milestone for knowledge transfer at IRB Barcelona, as it is the first time a product born from research developed at the Institute has reached patients in South Korea.

The MAF Test® predicts the prognosis of breast cancer patients and helps oncologists identify patients potentially receptive to the prevention of recurrence and who may benefit from adjuvant treatment with bisphosphonates, which are commonly used to treat osteoporosis. The test also makes it possible to identify patients for whom this treatment might not be appropriate.

Breast cancer is the most common form of cancer among women, with more than 2 million new cases diagnosed globally each year. Approximately 1 in 8 women will develop breast cancer in their lifetime and, of these, 15–20% will eventually develop metastases. In South Korea, more than 34,000 women are newly diagnosed with breast cancer each year.

This agreement adds to the distribution alliances signed by Inbiomotion with Palex Medical for Spain and Portugal, The Scientific Group for Sub-Saharan Africa, Source BioScience for the United Kingdom and Ireland, and SPA Farma for Italy. With the addition of South Korea, the IRB Barcelona spin-off further expands the international presence of a technology that has come about from biomedical research conducted in Barcelona.